
|Articles|May 28, 2020
ASCRS 2020: Eyevance portfolio brimming with product launches
Author(s)Alex Delaney-Gesing
Advertisement
Ophthalmology Times' Sheryl Stevenson speaks with Julie Speed, chief commercial officer of Eyevance Pharmaceuticals, on what's on the agenda for the company's porfolio this year with product launches during the 2020 ASCRS virtual meeting.
See more ASCRS coverage here
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Dry Eye Awareness Month: building a strong optometry-ophthalmology co-management model
3
FDA grants priority review to Satralizumab sBLA for thyroid eye disease
4
REGENXBIO doses first patient in NAAVIGATE, phase 2b/3 sura-vec trial for diabetic retinopathy
5
























